Posted by Michael Wonder on 23 May 2024
Setmelanotide acetate for the treatment of patients with obesity and hyperphagia in Bardet-Biedl syndrome (final guidance)
22 May 2024 - NICE has published final evidence-based recommendations on the use of setmelanotide acetate (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over.
Setmelanotide acetate is recommended as an option for treating obesity and hyperphagia in genetically confirmed Bardet-Biedl syndrome in people aged 6 years and over, only if they are aged between 6 and 17 years when treatment starts. These people can carry on having setmelanotide as adults until they need to stop. Setmelanotide acetate is only recommended if Rhythm Pharmaceuticals provides it according to the commercial arrangement.
